Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1994 Jan 1;179(1):341-6.
doi: 10.1084/jem.179.1.341.

Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival

L Qin  1 , K D Chavin, J Lin, H Yagita, J S Bromberg
Affiliations

Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival

L Qin et al. J Exp Med. .

Abstract

Indefinite graft survival was obtained with murine cardiac allografts using the combined administration of monoclonal antibodies (mAbs) directed against the receptor ligand pair CD2-CD48. Although each antibody could prolong graft survival when given alone, neither resulted in the indefinite graft survival seen with the combination. Combined mAb administration is associated with inhibition of T cell priming and help and subsequent cytotoxic T lymphocyte generation. This indicates that the interaction between CD2 and its ligand is important for antigen priming and recognition, and combined mAbs may prove to be a useful therapeutic regimen for transplantation.

PubMed Disclaimer

References

    1. FASEB J. 1991 Jun;5(9):2292-9 - PubMed
    1. J Exp Med. 1991 Nov 1;174(5):957-67 - PubMed
    1. Transplantation. 1971 Mar;11(3):298-302 - PubMed
    1. J Immunol. 1976 Mar;116(3):868-75 - PubMed
    1. J Exp Med. 1979 Jan 1;149(1):273-8 - PubMed

Publication types